Johnson & Johnson (NYSE:JNJ) Stock Forecast

sophia agwaonye
Ad disclosure WeInvests is an independent platform with the mission of simplifying financial decisions. Therefore, we work with independent professionals to offer you the latest news. We may receive compensation if you click on certain links, sponsored posts, products and/or services, transferring leads to brokers, or advertisements. We do our utmost best to ensure you will not incur any disadvantages as a user. No rights can be derived from the Content we provided on or through our website, nor should this be considered as legal, tax, investment, financial or other advice. The Content is for informational purposes only. In case of any doubt, you should seek advice from an independent financial advisor. Read More >>

This content represents the writer’s opinions and research and is not intended to be taken as financial advice. The information presented is general in nature and may not meet the specific needs of any individual or entity. It is not intended to be relied upon as a professional or financial decision-making tool.

Johnson & Johnson (J&J) is a company that does research, development, manufacturing, and selling of different types of products. These products include medicine, medical devices, and things that people use every day.

Their medicine can help people with different types of health problems, like immune diseases, cancer, neurological disorders, infections, and heart problems. They also make things that people use at home, like toothpaste and medicine for when you’re feeling sick.

J&J also creates things that doctors and other healthcare professionals use to treat patients. This includes medical devices that can help with heart problems, bone and joint issues, surgery, and even vision problems.

They sell their products in many parts of the world, including the United States, Europe, Asia-Pacific, Africa, and other parts of the Western Hemisphere. They work with different types of stores and businesses to make sure that their products are available to people who need them.

J&J’s headquarters is located in New Brunswick, New Jersey, in the United States. Johnson & Johnson’s shares are part of the Dow Jones Industrial Average. They’re also a big company that makes a lot of money, and it’s number 36 on the Fortune 500 list for 2021. This list shows the biggest companies in the United States based on how much money they make.

Johnson & Johnson is worth a lot of money, and they’re considered to be one of the most valuable companies in the world. They’re so good at managing their money that they have a really high credit rating of AAA, which is even better than the credit rating of the United States government. Only one other American company has this high rating.

Johnson & Johnson Stock Forecast 2023

As of March 3, 2023, Johnson & Johnson was trading at $152.45 after starting the year above $180. This is about a 15% drop since the beginning of the year.

Johnson & Johnson may be correcting, which would be the first correction since 2019/2020. It is natural for prices to drop in the financial market, as this is the only way to get higher prices. We forecast that Johnson & Johnson will be trading around $140 by Q3 of 2023, and we will experience a market recovery by the final quarter of the year. 

There are lots of factors that can influence the price of a stock, Johnson & Johnson has a strong history of not being influenced easily by external factors such as a recession. 

Johnson & Johnson Stock in 2022

In 2022, Johnson & Johnson announced that it would acquire Abiomed, which is a medical heart pump device company. This acquisition would cost almost $17 million, which might be a lot of money for other companies but not for Johnson & Johnson. Heart disease is a very popular health problem around the world, with more than 850,000 cases reported yearly, which makes Abiomed relevant.

This acquisition is the most significant activity for Johnson & Johnson in 2022. This move should tentatively make this stock’s price increase, as Abiomed will be a good source of revenue for Johnson & Johnson and the company was looking to pay in cash. However, that wasn’t the case, as price was in a range close to its all-time high in 2022. 

By the end of 2022, the price was trading at $180, and it seems like the Abiomed acquisition had no significant impact on price. With all of this, it is safe to say that demand and supply were the major factors driving prices in 2022.

By December 2022, Johnson & Johnson announced that they were not able to meet their 2022 target, which could be the reason for the crash we are experiencing in the first quarter of 2023. 

Johnson & Johnson Stock in 2021

As of the beginning of 2021, Johnson & Johnson was trading at around $150 per share. Its stock price went up over 13% in the first quarter of 2021, due to improved sales of pharmaceutical drugs and COVID-19 vaccines. In the 2nd quarter of 2021, the company continued to profit from market share gains and sales of some of its vital drugs. Its medical devices business continued to increase in volume, and all these factors caused its stock price to hit an all-time high of $180 per share in August 2021.

In September 2021, there was a huge sell-off in its pharmaceutical stocks, which caused J&J’s stock price to fall to $165 per share. Biden’s federal agenda to reduce the cost of healthcare was also an additional reason for the sell-off in September 2021.

4hr Johnson & Johnson chart for 2021

After the sell-off, J&J’s stock price was attractive, and there was a buyback, which caused the stock price to increase.

Johnson & Johnson Stock in 2020

In 2020, JNJ started with a stock price of $145 per share, and as we all know, there was a global pandemic in the year 2020, which caused the financial market to collapse globally. The world was on lockdown to prevent the spread of covid-19. J&J’s stock price fell by 24% to around $110 but quickly recovered as Johnson & Johnson helped with meditation for covid-19. 

4hr Johnson & Johnson chart for 2020

In May 2020, Johnson & Johnson decided to stop producing and distributing baby powders that have talc among their contents. This was because talc contained asbestos, which is a known agent that causes cancer. Before the discontinuation of talc contained products, JNJ faced several lawsuits that affected their stock price. 

Johnson & Johnson Stock in 2019

Johnson & Johnson was ranging all through 2019, with technical analysis and demand and supply being the determinants of price. Johnson & Johnson started 2019 with its stock price at $127 per share, after which it experienced a rally before declining. These movements in price were caused by buyers and sellers, as there were no fundamentals that could have caused those price spikes.

4hr Johnson & Johnson chart for 2019

Johnson & Johnson Stock in 2018

J&J started the year 2018 with an opening price of $128, which reached a high of $148 per share before significantly crashing to $122. The crash between the end of January and the beginning of February was a result of a lawsuit. Johnson & Johnson was accused of using a cancer-causing agent in the production of its body creams.

This lawsuit really affected Johnson & Johnson, with the price going as low as $118, which was a very notable dump. The stock price eventually went up again as more investors saw that dip in price as an opportunity to add JNJ to their portfolios. 

4hr Johnson & Johnson chart for 2018

There was a massive sell-off in December after price reached a notable supply zone of around $148 per share. This drop pushed price to $122, which was the next demand zone.

Johnson & Johnson Stock in 2017

2017 was a very bullish year for JNJ, in part because of its two acquisitions and sales of drugs. Johnson & Johnson acquired Actelion Pharmaceuticals, a Swiss biotech company, for $30 billion. The acquisition gave Johnson & Johnson access to Actelion’s portfolio of drugs for rare diseases.

4hr Johnson & Johnson chart for 2017

In February 2017, Johnson & Johnson acquired Abbott Medical Optics, a subsidiary of Abbott Laboratories, for $4.3 billion. The acquisition expanded Johnson & Johnson’s presence in the eye care market and gave the company access to Abbott Medical Optics’ products for cataract surgery and laser vision correction.

These acquisitions attracted lots of investors as the stock price continued to rise.


Johnson & Johnson’s stock price movements can be influenced by a variety of factors, including the company’s financial performance, news and developments, market conditions, and broader economic trends. The company has a long history of stability and reliability. However, as with any investment, it’s important to conduct thorough research and analysis before making any decisions. 

By staying informed about the various factors that can impact Johnson & Johnson’s stock price, investors can make more informed decisions about when to buy or sell. Johnson & Johnson remains a major player in the healthcare industry and its stock price movements will continue to be closely watched by investors and analysts alike.


How can I stay informed about Johnson & Johnson’s stock price movements?

There are several ways to stay informed about Johnson & Johnson’s stock price movements, including following financial news and analysis, monitoring the company’s quarterly earnings reports and SEC filings, and keeping track of broader economic trends.

What should I consider before investing in Johnson & Johnson?

Before investing in Johnson & Johnson, you should consider factors such as your investment goals, risk tolerance, and portfolio diversification strategy. It’s also important to conduct thorough research and analysis to determine whether the company’s stock is a good fit for your investment portfolio.

Is Johnson & Johnson a good investment?

Johnson & Johnson has a long history of stability and reliability. However, as with any investment, it’s important to conduct thorough research and analysis before making any decisions.

Risk Disclaimer

WeInvests is a financial portal-based research agency. We do our utmost best to offer reliable and unbiased information about crypto, finance, trading and stocks. However, we do not offer financial advice and users should always carry out their own research.

Read More